This review concluded that fluconazole and echinocandins were generally associated with lower risks of treatment termination and adverse liver events. Itraconazole and voriconazole was associated with a higher risk of liver injury. Limitations in the analysis mean that these conclusions are unlikely to be reliable.
Study selection
Randomised controlled trials (RCTs) that assessed empirical, pre-emptive or definitive standard antifungal therapy mostly in adults with suspected or documented invasive fungal (Aspergillus, Candida) infections or persistent febrile neutropenia were eligible for inclusion. Studies conducted exclusively in children, asymptomatic patients and patients with superficial or mucocutaneous fungal infections were excluded. Studies of infusion-related or renal toxicity and studies of combination antifungal treatments were excluded. Data from non-randomised studies, cohort studies and case series were included in an auxiliary analysis.
The primary outcome was incidence of patients who withdrew due to adverse reactions. Secondary outcomes were cumulative incidence of patients who stopped treatment due to abnormal liver function tests and the cumulative incidence of patients who developed abnormal liver function tests during treatment but not require discontinuation. Studies had to report data on one such outcome to be included in the review. Thresholds for abnormal liver function were based on values reported in the primary studies.
Included studies were head-to-head comparisons of various antifungal agents or different doses of the same agent. The most commonly assessed antifungal agent was amphotericin B. Other agents included itraconazole, fluconazole, voriconazole, anidulafungin, caspofungin and micafungin. Mean age ranged from 18 to 61 years. The proportion of patients with neutropenia ranged from zero to 100%. The proportion of patients with leukaemia ranged from zero to 100%. The proportion of transplant patients ranged from zero to 69%.
Two reviewers independently assessed studies for inclusion.
Assessment of study quality
Two reviewers independently assessed allocation concealment, sequence generation, blinding of patients and investigators and availability of data on an intention-to-treat basis.
Data extraction
Two reviewers independently extracted data on the proportion of patients with each outcome of interest in each treatment arm. No measures of effect that compared results between trial treatment groups were calculated. Disagreements were resolved through discussion.
Methods of synthesis
Summary cumulative incidence rates and 95% confidence intervals (CIs) were estimated using the maximum likelihood method and beta-binomial method and used to account for heterogeneity. Data were pooled for each treatment arm
